Welltower Inc. Common Stock vs 22nd Century Group Inc — how do they compare? Welltower Inc. Common Stock trades at $225.47 (market cap $159.33B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Welltower Inc. Common Stock is far larger — about 256293.5× 22nd Century Group Inc's market cap, and Welltower Inc. Common Stock pays a 1.54% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Welltower Inc. Common Stock for 1 Days and 22nd Century Group Inc for 32 Days on average.
| WELL | XXII | |
|---|---|---|
Market Cap | $159.33B | $621.67K |
Volume | 2,484,986 | 45,625 |
Sector | Real Estate | Consumer Staples |
52-Week High | $252.07 | $483.00 |
52-Week Low | $165.94 | $0.80 |
Typical Hold Time | 1 Days | 32 Days |
Enterprise Value | $177.09B | -$3.69M |
Dividend Yield | 1.54% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →